426 related articles for article (PubMed ID: 33648947)
1. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
Leone RD; Powell JD
Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
[TBL] [Abstract][Full Text] [Related]
2. NF-κB in the New Era of Cancer Therapy.
Eluard B; Thieblemont C; Baud V
Trends Cancer; 2020 Aug; 6(8):677-687. PubMed ID: 32409139
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
5. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
Grosser R; Cherkassky L; Chintala N; Adusumilli PS
Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
[TBL] [Abstract][Full Text] [Related]
6. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
Carosella ED; Gregori S; Tronik-Le Roux D
Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
Huo S; Liu L; Li Q; Wang J
Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
Front Immunol; 2020; 11():1109. PubMed ID: 32625204
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
Zhang F; Stephan SB; Ene CI; Smith TT; Holland EC; Stephan MT
Cancer Res; 2018 Jul; 78(13):3718-3730. PubMed ID: 29760047
[TBL] [Abstract][Full Text] [Related]
10. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming of terminally exhausted CD8
Guo Y; Xie YQ; Gao M; Zhao Y; Franco F; Wenes M; Siddiqui I; Bevilacqua A; Wang H; Yang H; Feng B; Xie X; Sabatel CM; Tschumi B; Chaiboonchoe A; Wang Y; Li W; Xiao W; Held W; Romero P; Ho PC; Tang L
Nat Immunol; 2021 Jun; 22(6):746-756. PubMed ID: 34031618
[TBL] [Abstract][Full Text] [Related]
14. Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.
Xiao L; Yeung H; Haber M; Norris MD; Somers K
Trends Cancer; 2021 Aug; 7(8):751-777. PubMed ID: 34183305
[TBL] [Abstract][Full Text] [Related]
15. Application of Bionanomaterials in Tumor Immune Microenvironment Therapy.
Wang J; Bao Y; Yao Y
J Immunol Res; 2021; 2021():6663035. PubMed ID: 33628850
[TBL] [Abstract][Full Text] [Related]
16. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
[TBL] [Abstract][Full Text] [Related]
17. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
Pellegrino M; Del Bufalo F; De Angelis B; Quintarelli C; Caruana I; de Billy E
Cells; 2020 Dec; 10(1):. PubMed ID: 33374128
[TBL] [Abstract][Full Text] [Related]
18. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
19. From antibodies to living drugs: Quo vadis cancer immunotherapy?
Szöőr Á; Szöllősi J; Vereb G
Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
